Trial Profile
A real world, retrospective, single centre experience with nivolumab in Indian patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results (n=28) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
- 27 Jun 2018 New trial record
- 05 Jun 2018 Results (n=15) presented at the 54th Annual Meeting of the American Society of Clinical Oncology